The hepatitis C virus (HCV) is a transmissible viral infection that is often asymptomatic in the early stages of the disease, but can progress to serious liver complications including cirrhosis and hepatocellular cancer over years or decades with grave consequences for health and medical costs. [2-4] A discrete time Markov model was developed in Excel to simulate the progression of an HCV-susceptible population through infection, acute, and then chronic HCV, as depicted in Exhibit A1 below. The population in each stage of disease was updated at each time step by cycling the model. The time step (or model cycle duration) was taken to be one year. The Metavir scoring system, designed to quantify the degree of liver fibrosis in patients with liver diseases such as HCV, was used to define disease severity for different stages of the model. [5] The Metavir scoring system is described in Table A1 .
Exhibit A1. Hepatitis C Transmission Simulation Model Schematic
Upon initial infection, patients enter an "acute" phase which they must leave after one model cycle. They may die, spontaneously clear the disease without treatment, or progress to "chronic" disease, consisting of seven stages of liver damage: Metavir scores F0-F4, decompensated cirrhosis (DC) and hepatocellular carcinoma (HCC). Patients may stay in any disease state except acute for more than one cycle.
Patients in stage F0 or higher may receive HCV treatment during the simulation; if not cured, treated patients may progress or die at the same rates as infected and untreated patients. If HCV is cured in stages F0-F2, patients are no longer infectious and liver damage is assumed to be reversed. [6, 7] These patients return to the susceptible population with healthy livers; if reinfected, they re-commence disease progression at the acute stage.
Patients cured of HCV in stages F3 and higher are no longer infectious, but may progress to additional liver damage more slowly than patients with uncured HCV. [8] They are susceptible to re-infection at the same rate as patients without liver damage, but if re-infected, re-enter the infected population with their existing level of liver damage. Patients with DC or HCC who are cured of HCV are no longer infectious and become eligible for liver transplants. The transplant stage lasts exactly one cycle, after which patients move to a post-transplant state. If these patients are re-infected, they re-enter the infected population with healthy livers at the acute stage. Consistent with current clinical practice, patients who are co-infected with HIV (all patients in the sexual exposure group, more details described below) are not eligible for liver transplants. [9, 10] 
Populations Modeled
Three distinct subpopulations are modeled, defined by their HCV exposure route: healthcare (HC), injection drug use (ID), and sexual (SX). The three exposure groups are modeled independently-an individual can belong to only one exposure group for the duration of the simulation. There is assumed to be no ongoing transmission in the HC exposure group, and because it is a closed cohort, the HC population shrinks over time, and is assumed to be aging and subject to increasing mortality rates over the course of a simulation. The ID and SX exposure groups are assumed to have constant mortality rates and experience ongoing entry and exit such that their size remains constant over the simulation.
Within each exposure group, the four HCV genotypes most common in Germany (genotypes 1, 2, 3 and 4) are modeled. [11, 12] This permits us to model HCV prevalence and transmission with greater nuance, and to account for the fact that different genotypes respond differently to treatment; [13] may progress at different rates; [14, 15] and involve different mortality risks. [16] Patients may only be infected with one genotype at a time, but once cured, a patient can be reinfected with any of the three genotypes. Because their treatment options and cure rates are similar, genotypes 1 and 4 are modeled together, blended at their proportions in the German prevalent population. Genotypes 2 and 3 are modeled separately.
Transmission Function
In the ID and SX exposure groups, for each genotype, the rate at which individuals are infected is modeled dynamically as a function of the number in the exposure group who are currently infected with the given genotype. Individuals who are uninfected (susceptible) at the beginning of a year t are at risk of becoming HCV infected and the probability of becoming infected during year t (i.e., the annual incidence rate) is given by:
where t is the year, is the number of people infected at the beginning of year t, and is the number of people susceptible at the beginning of year t. The transmission model specified by equation (1) assumes that the incidence rate is proportional to the fraction of individuals in an exposure group who are infected. The proportionality constant K is calibrated to ensure that the incidence rate (the left side of equation 1) matches the empirical estimate of disease incidence rate at model start (t=0):
The incidence rates and proportionality constants K for each exposure group by genotype are reported in Table A2 . 
Treatment Scenarios
Four treatment scenarios are modeled, as described in the main article and detailed in Table A3 . The scenarios differ by treatment capacity, that is, the number of patients who can be treated in a model cycle, and how that capacity changes over time. In all scenarios, any patient with diagnosed HCV is eligible for treatment as long as there is sufficient treatment capacity available, and there are no diagnosed patients with more serious liver disease who are untreated (that is, patients with more serious liver disease are treated before those with less serious liver disease). In all scenarios, patients are treated with the regimens currently in use in Germany for their genotype, fibrosis level and HIV-coinfection status. SVR rates are assumed to follow clinical trial results, and regimen costs in the first 15 years of the simulation are taken from Stahmeyer et al. 2015 . [22] After 15 years, all regimen drugs are assumed to be subject to generic price competition, causing their starting cost to fall by 79%. [23] Regimen drugs, duration, efficacy and costs differ by infection genotype and fibrosis score, as detailed in Table A3 . The scenarios involve treating all diagnosed patients in order of the severity of their liver disease in each cycle until the total treatment capacity for that model cycle is exhausted. In the next cycle, treatment resumes with additional capacity, again starting with the most severe diagnosed patients. The diagnosis rate is assumed to be 65% across all disease states [34] , and each cycle, previously infected but undiagnosed patients are newly diagnosed, so that the population of patients available for treatment is continually refreshed. (2015) and Stahmeyer et al. (2014) . [33, 38] The distribution of the infected population by exposure group, genotype, and disease stage is given in Table A4 . 
Starting Populations

Model Outputs
Each year, the model produces the number of people in every disease state. Patients who die within a cycle are assumed to transition out of the simulation following a uniform probability distribution with a mean of six months. Model outputs for such patients are calculated as half the values as for those who don't die during the cycle.
Model Parameters
Model parameters are taken from the published literature, with efforts made to find exposure group-and genotype-specific values wherever possible. The Healthcare exposure group was defined to be German residents aged 35+, consistent with the "Check-up 35+" program discussed in Wolffram et al. 2015[39] It is modeled with a mortality rate that increases at 7% per year as the closed cohort, which has a starting average age of 57 years ages over time. [42] Model parameters for the healthcare exposure cohort and their sources are provided in Table A5 .
The ID exposure group has the highest incidence rate, reflecting the greater transmission among this population. [19, 43] Model parameters for the ID cohort and their sources are provided in Table A6 .
The Sexual exposure group is characterized by co-infection with HIV, which affects the progression of HCV [44] , and in our analysis is principally composed of men who have sex with men. Model parameters for the Sexual exposure group and their sources are provided in Table  A7 .
Annual Mortality Rates
Disease stage-, exposure group-, and genotype-specific annual mortality rates were modeled using a multiplicative form-Let M(a,e,g,s) represent the annual mortality rate for a person who is age a, exposure group e, HCV infected with genotype g, and stage of liver disease s (for stages F0-F4-see below for a discussion of patients with DC and HCC). The multiplicative mortality model assumes:
where M 0 (a) is the base annual mortality rate for a person aged a in Germany, and K e , K g , K s are proportionality constants that account for a person's exposure group, HCV genotype, and stage of liver disease, respectively. Base mortality rates are gender-weighted and taken from German census data; [45] the healthcare exposure group is comprised of males and females aged 35+, the injection drug exposure group is comprised of males and females aged 20-69, and the sexual exposure group is comprised of males aged 18 and over. Because DC and HCC are such serious diseases with very high mortality, we do not model mortality for these states in the same way as for less severe disease (F0-F4). Instead, we use the same estimates used by Younossi et al. "Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients," Journal of Hepatology 2014 vol. 60 j 530-537 who reports all-cause one-year mortality rate for DC = 0.135 and for HCC = 0.427. [51] No further adjustment for genotype, exposure group, etc. are made to these estimates, although we do allow for dependence on age as follows.
The mortality model we use for the advanced stages of liver disease DC and HCC is:
We estimated the proportionality constants K dc and K hcc as follows: K dc = 0.135/M 0 (a dc ) where M 0 (a dc ) is the annual baseline mortality rate at the average age a dc of the group of persons with DC from which the mortality rate 0.135 was derived (a dc = 66 in the Planas et al. study from which the 0.135 estimate was derived). [52] Similarly, K hcc = 0.427/M 0 (a hcc ), where a hcc = 70, the age at which HCC "reaches a peak" according to El-Serag (2011). [53] Using this approach, we have the proportionality constants K dc = 12.06, and K hcc = 25.95.
To calculate mortality rates for those with DC or HCC who have achieved SVR, we apply a factor of 0.75 to the uncured mortality rate, based on van der Meer et al. [48] K e
The healthcare exposure group was used as the reference group, and their K e set at 1.0. For the ID exposure group, Mathers et al (2013) provides a systematic review of the mortality of people who inject drugs (PWID), calculating a standardized mortality rate ratio of 17.52 in Western Europe. [54] However, some of the excess mortality among PWID reflected in the 17.52 figure is attributable to HCV infection and thus is already accounted for by other proportionality constants in our model (K s and K g ), whereas K e represents the age adjusted mortality rate ratio for HCV uninfected drug users compared to the general population. To estimate K e , we express the mortality rate for intravenous drug users at age a (called M(a,e) below) as a weighted average of the mortality rates for HCV infected PWID (stratified by genotype and disease stage) and uninfected PWID: For the SX exposure group, Ehren et al (2014) provide an estimate for the annual mortality risk for HIV+MSM of 0.00867 in Germany, which we divide by the baseline mortality risk for German males age 18+ to generate a standardized mortality ratio of 2.77 for uninfected HIV+MSM. [55] Following the same approach as outlined above for the ID exposure group, we calculate K e = 1.30 for the sexual exposure group.
Incorporating all of these factors according to equation (3) generates annual mortality rates that are specific to exposure group, genotype and disease stage, as indicated in tables A5-A7 below.
Since the healthcare exposure group is a closed cohort whose average age increases over the simulation, we assume that the background mortality rate grows at 14.4% per year in this group, based on the average annual increase in mortality rate for the population who were aged 57 in 1990, from 1990 to 2011.
[42] For the other two exposure groups, we assume a stable age distribution, or that the exiting of older individuals is offset by ongoing entry of younger individuals into these exposure groups, and assume a constant background mortality. While it is possible that improved treatments may lead to slight aging of these two exposure groups, those effects could be offset by younger ages at entry into the groups (e.g., younger age at initiation of drug use or sexual activity). Accordingly, in the absence of clear trends on the ages of initiation for these risk behaviors, we have opted for the simplest plausible assumption of a stable (stationary) age distribution in the PWID and sexual exposure groups over the time span of our forecasts.
Employment
To calculate employment levels in each scenario, we multiplied the number of patients in each category (for example, a sexual exposure group patient with active HCV and fibrosis score F3) by the probability of such a patient being employed. For uninfected patients, we used information from the OECD 2014 Employment statistics, 2011 German population statistics and Dirks et al (2012) to calculate the probability of employment for uninfected individuals in each exposure group. For HC and SX infected patients, we used estimates from Stahmeyer (2014) of the probability of employment for an infected individual in each fibrosis severity state. [56] [57] [58] [59] For the IV drug user category, The Centre for Drug Research finds average employment of 23% in Germany among the entire group, including both HCV infected and uninfected. [60] This rate is lower than the Stahmeyer (2014) average employment rate of 49.2% among HCV infected. It likely is implausible that curing an IV drug user of HCV would reduce his or her probability of employment, so for the IV exposure group we assumed that the change in employment probability resulting from SVR was zero. We summed the total number employed in each scenario and calculated the difference across scenarios to estimate the change in employment resulting from different treatment capacities. Since our overall estimates of employment changes resulting from different treatment scenarios only include the effects in the HC and SX exposure groups, they should represent conservative estimates. 
Sensitivity Analyses
We conducted sensitivity analyses along several dimensions, exploring the impact of changes in key variables on social value, total infected population after 30 years, and the time needed for the infected population to fall below 5,000. These results are presented in Tables A8 and A9 . Compared to the Baseline of 25,000 patients treated per year, the scenarios treating 15,000 and 35,000 patients per year yield was €2.49b less and €1.35b more social value, respectively. 
